Percutaneous coronary intervention before transcatheter aortic valve implantation: A propensity score matched analysis.

All-cause mortality Percutaneous coronary intervention Stable coronary artery disease Stroke Transcatheter aortic valve intervention

Journal

Cardiovascular revascularization medicine : including molecular interventions
ISSN: 1878-0938
Titre abrégé: Cardiovasc Revasc Med
Pays: United States
ID NLM: 101238551

Informations de publication

Date de publication:
22 Mar 2024
Historique:
received: 06 11 2023
revised: 22 02 2024
accepted: 18 03 2024
medline: 30 3 2024
pubmed: 30 3 2024
entrez: 29 3 2024
Statut: aheadofprint

Résumé

The role of percutaneous coronary intervention (PCI) in patients with stable coronary artery disease (CAD) who subsequently undergo transcatheter aortic valve replacement (TAVR) remains uncertain. Therefore, we conducted this study to assess the association of PCI before TAVR with mortality and cardiovascular outcomes. We used the TriNetX database (Jan 2012 - Aug 2022) and grouped patients into PCI (3 months or less) before TAVR and no PCI. We performed propensity score matched (PSM) analyses for outcomes at 30 days and 1 year. Of 17,120 patients undergoing TAVR, 2322 (14 %) had PCI, and 14,798 (86 %) did not have PCI before TAVR. In the PSM cohort (2026 patients in each group), PCI was not associated with lower all-cause mortality at 30 days (HR: 1.25, 95 % CI: 0.82-1.90) or 1 year (HR: 1.02, 95 % CI: 0.83-1.24). Frequency of repeat PCI after TAVR was low in both no PCI vs. PCI (2.4 % vs. 1.2 %) at 1 year; PCI was associated with a lower rate of repeat PCI (HR: 0.49, 95 % CI: 0.30-0.80). Sensitivity analysis revealed an E-value of 3.5 for repeat PCI (E-value for lower CI for HR: 1.81). PCI was not linked to reductions in MI, heart failure exacerbation, all-cause hospitalization, major bleeding, or permanent pacemaker/implantable cardioverter defibrillator. This analysis showed that PCI prior to TAVR was not associated with improvement in all-cause mortality. However, PCI was associated with a reduced rate of repeat PCI at 1 year.

Sections du résumé

BACKGROUND BACKGROUND
The role of percutaneous coronary intervention (PCI) in patients with stable coronary artery disease (CAD) who subsequently undergo transcatheter aortic valve replacement (TAVR) remains uncertain. Therefore, we conducted this study to assess the association of PCI before TAVR with mortality and cardiovascular outcomes.
METHODS METHODS
We used the TriNetX database (Jan 2012 - Aug 2022) and grouped patients into PCI (3 months or less) before TAVR and no PCI. We performed propensity score matched (PSM) analyses for outcomes at 30 days and 1 year.
RESULTS RESULTS
Of 17,120 patients undergoing TAVR, 2322 (14 %) had PCI, and 14,798 (86 %) did not have PCI before TAVR. In the PSM cohort (2026 patients in each group), PCI was not associated with lower all-cause mortality at 30 days (HR: 1.25, 95 % CI: 0.82-1.90) or 1 year (HR: 1.02, 95 % CI: 0.83-1.24). Frequency of repeat PCI after TAVR was low in both no PCI vs. PCI (2.4 % vs. 1.2 %) at 1 year; PCI was associated with a lower rate of repeat PCI (HR: 0.49, 95 % CI: 0.30-0.80). Sensitivity analysis revealed an E-value of 3.5 for repeat PCI (E-value for lower CI for HR: 1.81). PCI was not linked to reductions in MI, heart failure exacerbation, all-cause hospitalization, major bleeding, or permanent pacemaker/implantable cardioverter defibrillator.
CONCLUSION CONCLUSIONS
This analysis showed that PCI prior to TAVR was not associated with improvement in all-cause mortality. However, PCI was associated with a reduced rate of repeat PCI at 1 year.

Identifiants

pubmed: 38553281
pii: S1553-8389(24)00099-X
doi: 10.1016/j.carrev.2024.03.011
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Safi U Khan (SU)

Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, Houston, TX, United States. Electronic address: safinmc@gmail.com.

Sourbha S Dani (SS)

Division of Cardiology, Lahey Hospital and Medical Center, Beth Israel Lahey Health, Burlington, MA, United States.

Sarju Ganatra (S)

Division of Cardiology, Lahey Hospital and Medical Center, Beth Israel Lahey Health, Burlington, MA, United States.

Talha Ahmed (T)

Department of Cardiovascular Medicine, The University of Texas at Houston-Memorial Hermann Heart & Vascular Institute, Houston, TX, United States.

Amro Agalan (A)

Sands-Constellation Heart Institute Rochester General Hospital Rochester, NY, United States.

Sumanth Khadke (S)

Division of Cardiology, Lahey Hospital and Medical Center, Beth Israel Lahey Health, Burlington, MA, United States.

Siddharth Agarwal (S)

Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.

Syed Zaid (S)

Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, Houston, TX, United States.

Hassaan B Arshad (HB)

Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, Houston, TX, United States.

Salman Zahid (S)

Sands-Constellation Heart Institute Rochester General Hospital Rochester, NY, United States.

Alpesh R Shah (AR)

Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, Houston, TX, United States.

Sachin S Goel (SS)

Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, Houston, TX, United States.

Neal S Kleiman (NS)

Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, Houston, TX, United States.

Classifications MeSH